EXPLORE!

Liver Update Benefits of Liv.52 in Hepatomegaly syndrome in pediatric population

  1754 Views

eMediNexus    27 September 2021

A hepatomegaly syndrome in children also known as Debre’s syndrome II as and Baker-Winegard syndrome. It is characterized by hypotonia associated with accumulation of fat and glycogen in the liver caused by disorder of carbohydrate and lipid metabolism. It has varied etiology. Various approaches are employed for the management of hepatomegaly syndrome, one of which includes Liv. 52 therapy.

The investigators of the present study assessed the efficacy and safety of Liv.52 in children suffering from hepatomegaly syndrome associated with or without viral infection. A total of 71 children with hepatomegaly syndrome, aged between 2 and 17 years were enrolled in trial which were studies over a period of six months. Among which, 51 were administered Liv.52 syrup, while 20 were included as control group. The protocol included administration of Liv.52 syrup in following dose; 2.5 ml twice daily for children under 12 years of age and 5 ml twice daily for children above 12 years.

All the children were examined at 2, 4 and 6 months as Liv52 treatment was discontinued after four months. Effectiveness of therapy was determined as improvement of appetite, well-being, gain in the weight and waist size, and relief from nausea, enhancement in the liver function tests and reduction in hepatomegaly which was evident by clinical examination as well as ultrasonography.

The main biochemical markers examined were asparatate and alanine transaminase (AST and ALT), lactic-dehydrogenase (LDH), gamma-glutamic transpeptidase, imunoglobulins, and serum proteins especially albumin. 

The results divulged that children who were treated with Liv.52 syrup showed amelioration in asthenia, suggestive of weight gain. They also showed remarkable improvement in appetite, dynamic daily activities and reduced nausea. Furthermore, reduced liver and spleen size was also observed during the first 4 months of the treatment with Liv.52 syrup. Significant decrease in AST and ALT values and LDH level was also reported subsequent Liv.52 therapy.

Pediatric population who were treated with Liv.52 also accelerated the synthesis of gamaglobulins and improved protein synthesis which even remained at the normal level even after discontinuation of treatment. Gammaglutamic transaminase (GTT) was also found to be significantly reduced with Liv.52 treatment which was retained after discontinuation of drug. 

Thus, based on improvement in clinical signs and biochemical parameters, it is evident that Liv.52 therapy can be beneficial in the management of hepatomegaly syndrome in children.

Source: Marginean O,Micle I,Lesovici M,Balean R,Ioana. Use of hepatoprotective agents in hepatomegaly syndrome in children: An experience with Liv.52 Syrup. Medicine Update.2002;8(10):57-60.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.